WO2003045272A2 - ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ß-D-MANNURONIC ACID - Google Patents
ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ß-D-MANNURONIC ACID Download PDFInfo
- Publication number
- WO2003045272A2 WO2003045272A2 PCT/NO2002/000432 NO0200432W WO03045272A2 WO 2003045272 A2 WO2003045272 A2 WO 2003045272A2 NO 0200432 W NO0200432 W NO 0200432W WO 03045272 A2 WO03045272 A2 WO 03045272A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- content
- alginate
- fish
- immunostimulating
- solid
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 42
- 241000124008 Mammalia Species 0.000 title claims abstract description 16
- 241000270322 Lepidosauria Species 0.000 title claims description 8
- 229920000615 alginic acid Polymers 0.000 claims abstract description 111
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 111
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 84
- 229940072056 alginate Drugs 0.000 claims abstract description 84
- 239000000463 material Substances 0.000 claims abstract description 65
- 241000251468 Actinopterygii Species 0.000 claims abstract description 36
- 241000271566 Aves Species 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 71
- 239000000284 extract Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 34
- 239000007787 solid Substances 0.000 claims description 23
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 11
- 241001512709 Lessonia <stramenopiles> Species 0.000 claims description 11
- 241001474374 Blennius Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002417 nutraceutical Substances 0.000 claims description 7
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000007909 solid dosage form Substances 0.000 claims description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 235000021056 liquid food Nutrition 0.000 claims description 6
- 239000012669 liquid formulation Substances 0.000 claims description 6
- 235000021055 solid food Nutrition 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 5
- 230000004584 weight gain Effects 0.000 claims description 4
- 235000019786 weight gain Nutrition 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241001466453 Laminaria Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000938605 Crocodylia Species 0.000 abstract description 6
- 239000000969 carrier Substances 0.000 abstract description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 241000282887 Suidae Species 0.000 description 27
- 239000002245 particle Substances 0.000 description 15
- 241000195493 Cryptophyta Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000835 fiber Substances 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 241000922583 Anarhichas minor Species 0.000 description 6
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000019254 respiratory burst Effects 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000000080 chela (arthropods) Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 241000172184 Durvillaea antarctica Species 0.000 description 2
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001260563 Lessonia nigrescens Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000512260 Ascophyllum Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000304827 Durvillaea potatorum Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001512723 Ecklonia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000296380 Laminaria hyperborea Species 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 241001491708 Macrocystis Species 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000005613 guluronic acid group Chemical group 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- -1 hetero polysaccharide Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- SISQKQNJHCDULL-UHFFFAOYSA-N methyl benzenecarboximidate Chemical compound COC(=N)C1=CC=CC=C1 SISQKQNJHCDULL-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- MSXHSNHNTORCAW-MPGIDXPLSA-M sodium;(3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@@H]1OC(C([O-])=O)[C@@H](O)[C@H](O)[C@@H]1O MSXHSNHNTORCAW-MPGIDXPLSA-M 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention is directed to an oral, immunostimulating material for mammals, birds, fish, and reptiles comprising an immunostimulating amount of an alginate having a (1-
- the present invention is also directed to a method for stimulating the immune system of a mammal, bird, fish, or reptile comprising orally administering the inventive material to a mammal, bird, fish, or reptile.
- Alginates are isolated from marine brown algae. Alginate is also produced in some soil bacteria such as Azotobacter vinelandii and Azotobacter crococcum and several different Pseudomonas sp. Brown alga are however generally the source of commercially available alginates.
- Alginates are salts of alginic acid, a linear, hetero polysaccharide consisting of
- the polymers exist as homopolymer sequences of mannuronic acid, called M-blocks, homopolymer sequences of guluronic acid called G-blocks, and mixed sequences of mannuronic and guluronic acid units, designated MG-blocks or alternating blocks.
- M-blocks homopolymer sequences of mannuronic acid
- G-blocks homopolymer sequences of guluronic acid
- MG-blocks mixed sequences of mannuronic and guluronic acid units
- Alginates usually contain all three types of blocks and a block mostly consists of three to thirty monomer units.
- the distribution of the blocks depends on the type of algae from which the alginate is isolated, as well as on the age and part of the plant, for example alginate from the stem may have a different sequence and block composition to alginate isolated from the leaves.
- the time of year at which the algae are harvested also affects the block composition and sequence.
- the highest G-content can be found in the stem of old L.hyperborea.
- the leaf of the same species has a somewhat lower G-content and shorter G-blocks, but the content is still higher than most other species.
- Commercially available alginates usually have a G-content of 25%-70%.
- Alginates are known to be used in foodstuffs and in pharmaceutical, dental, cosmetic and other industrial products. The most common industrial applications are based on their hydrocolloidal and polyelectrolytic nature, which forms the basis for the gel-forming, thickening, stabilizing, swelling and viscosity-providing properties. Alginates that are rich in M content have also been shown to possess immunostimulating activity useful as vaccine adjuvants and wound-healing compositions as described in U.S. Patent No. 5,169,840.
- the present invention is directed to an oral, immunostimulating material for mammals, birds, fish, and reptiles comprising an immunostimulating amount of an alginate having a M content of at least 40% and, if necessary or desired, an acceptable carrier.
- the present invention is also directed to a method of stimulating the immune system of a mammal, bird, fish, and reptile comprising orally administering an immunostimulating amount of an immunostimulating ingestible material to said mammal, bird, fish, and reptile, wherein said material comprises an alginate having a M content of at least 40% and, if necessary or desired, an acceptable carrier.
- Figure 1 is a graph showing the weight increase of pigs given feed containing alginates of the invention over a twelve week period.
- Figure 2 is a graph showing the serum level of total white blood cells in the pigs tested with alginates of the invention as compared to a control.
- Figure 3 is a graph showing the serum level of monocytes in the pigs tested with the alginates of the invention as compared to a control.
- Figure 4 is a graph showing the serum level of lymphocytes in the pigs tested with the alginates of the invention as compared to a control.
- Figure 5 shows the level of phagocytosis measured using blood from pigs fed Durvillea water extract as compared to a control.
- Figure 6 shows the oxidative burst measured using blood from pigs fed the Durvillea water extract as compared to a control.
- Figure 7 shows the immune response to an injected Human Serum Albumin experimental vaccine for pigs fed Durvillea standard extract, Durvillea water extract and Lessonia standard extract as compared to a control.
- Figure 8 shows the specific growth rate (% growth per day) of spotted wolffish fed with oral feed containing Durvillea water extract over a sixty day period viz-a-viz the specific growth rate of a control group.
- Alginates having an M content of at least 40% are utilized as oral immunostimulators in the present invention for mammals, birds, fish, and reptiles. More specifically, alginates having an M content of 50% to 70% (such as derived from Lessonia, Durvillea, and Laminaria); 10% to 80%) (such as derived from Durvillea) and 80% to 99.9% (such as derived from bacteria and water extracts of alginates like Durvillea as prepared, for example, in accordance with the examples below) may be used. These alginates stimulate the immune response of mammals, birds, fish, and reptiles against disease or trauma caused by cellular attack by foreign bodies and physical injury of cells. Included among foreign bodies are microorganisms, particulate matter, chemical agents and the like. Included among physical injuries are mechanical wounds such as abrasions, lacertions, contusions, wounds and the like.
- the oral immunostimulating material and method of the present invention utilize an immunostimulating amount of the alginate having an M content of at least 40%.
- the immunostimulating amount can vary depending on the subject that is to ingest the immunostimulating material and the level of the immunostimulation that is needed. For example, without being limiting, for the first 60 days of a fish's life, orally administer 2-20 mg alginate/fish. Of course, more matured fish will require larger amounts.
- the oral immunostimulating material containing the alginate having an M content of at least 40% may be pharmaceutical, veterinary or nutraceutical solid dosage forms such as tablets, caplets, capsules, etc, or as a powder or liquid formulation. It may also be any type of solid or liquid food for mammalian, avian, ichthyic, or reptilian consumption such as pet food. It may also be a solid, semi-solid or liquid nutritional supplement such as food bars, drinks, etc.
- Acceptable carriers can be any of those conventionally used in pharmaceutical, veterinary and nutraceutical liquid or solid dosage forms, liquid, solid and semi-solid foods and liquid and solid nutritional supplements.
- the immunostimulating activity of the alginates of the invention stimulate the weight gain for a mammal (as demonstrated below in pigs (see Figure 1)) and a fish (as demonstrated below in spotted wolffish (see Figure 8 )) ingesting the alginate as compared to a control.
- This aspect is particularly useful and desirable when such alginates are orally given to young mammals.
- the present invention is also directed to a method for stimulating weight gain in mammals, birds, fish, and reptiles through immunostimulation comprising orally administering an immunostimulating amount of an immunostimulating material to the mammal, bird, fish, or reptile, wherein the material comprises an alginate having a M content of at least 40% and, if necessary or desired, an acceptable carrier. More specifically, this method also comprises administration of an alginate having an M content of 50% to 70%, 10% to 80% or 80% to 99.9%).
- the immunostimulating material may be any of those set forth above.
- the oral immunostimulating material of this invention can contain alginate having an M content of at least 40% that is synthetically derived or isolated from either alginate- producing bacterial species or seaweed sources.
- Alginates having an M content of at least 40% can be obtained from seaweeds by many processes known in the art.
- the starting material of the alginate having the required M content is algae or seaweed, in particular, brown algae which is generally treated with formaldehyde in order to fixate the phenols and preserve the algae.
- the algae can be washed with acid to remove the highly viscous laminaran and fucoglycans. Preferably, they can also be treated with alkali to reduce the content of pyrogens. It is understood that the algae can be pre-treated in any known manner.
- alginates most preferably, dried and milled algae of the species Durvillea can be used, but also fresh, whole or unmilled algae from Durvillea, Laminaria, Lessonia, Ecklonia, Macrocystis, or Ascophyllum are suitable as starting materials.
- alginates of the invention may also be prepared using a water extraction process by mixing an alginate source having a high M content with water in a ratio of 1:3 to 1:20 in a swelling step where the pH is kept
- solubilised alginate fraction from the solid material by filtration.
- An alginate having the required M content can be recovered from the solution by precipitation with acid, salt or alcohol.
- the suspension was then sieved on a 60-mesh filter and washed 2 times with an excess of water.
- the solution was then filtrated with filter aids on a vacuum funnel and thereafter on a pre filter of glass filter.
- the solution was then allowed to cool to 10 °C and was then added NaCl to a 0.5 % concentration. Thereafter drops of dilute 5.5 M hydrochloric acid were added by stirring with magnet to a pH 1.8. A white precipitate was formed.
- the suspension was,
- a sample from August 1996 of Durvillea antarctica milled to particles larger than 70 mesh was used as the starting material.
- 30 gram of dried algae was weighted in a vessel.
- 100 ml 0.2 M HC1 was added and the material was diluted with water to 500 ml. After a few minutes of stirring the pH increased to > 2.3 and acid was added to keep pH less than 2.3, (pH 1.8). After 2 minutes 2.5 ml of 0.2M HC1 was added.
- the material swelled very little when the pH was kept constant under pH 2.3 at pH 1.8, compared to swelling with pure water. After swelling for 1 hour, the material was sieved on 60 mesh filtration cloth, pressed by hand and transferred to a vessel.
- the resulting material was then added 500 ml of water and 50 ml soda ash/sodium hydroxide solution and extracted at 55 °C for 1 hour. The material swelled very quickly and became thick like a paste or pulp. It was stored by ambient temperature until next day. Then the material was further extracted for 1 hour at 55 °C and then milled on a mixer unit. Total mass was weighed to 549 gram. 150 gram of material was diluted with 700 gram of water under stirring. The solution was then filtrated on filter paper after addition of filter aids by means of vacuum from water suction. The amount of filtrate was measured to 564 gram and was cooled to 10°C.
- the fibers were drawn out by with pincer and then freeze-dried overnight with vacuum.
- the yield was weighed to 1.04 gram of alginate, corresponding to 3.6 weight % from the Durvillea Antarctica starting material.
- the content of M was 70 % and the block-distribution of the alginate measured by NMR as follows.
- the sieved solution was then filtrated in vacuo (water suction pump) on a funnel with filter paper.
- the viscosity of the filtrated solution was measured on a glass tube and the results are given in the following table.
- the filtrate was cooled to below 15°C and each of the samples were added drops of 5.5 M hydrochloric acid until the pH reached 1.8 - 2.0, under stirring with a magnetic stirrer. A fiber shaped precipitate was formed. The precipitate was then sieved on a 400-mesh filtration cloth and pressed by hand. The alginic acid was then diluted with water and neutralized with solid soda ash to pH 6-7 under stirring until completely solved. The solution was then cooled and precipitated with equal parts of isopropyl alcohol. Thereafter washed with 70 volume% isopropyl alcohol, and repeatedly washed with pure 100 volume % isopropyl alcohol. The precipitated fiber was pulled out with a pincer and transferred to a vessel and freeze dried overnight in vacuum. The results are shown in the following table, wherein the amount of yield was calculated assuming that no alginate was lost and that all the alginate is solved in the water added.
- the content of mannuronic acid in the separate fraction was further increased by addition of CaCl 2 .
- the starting material was D. antarctica from Chile that was milled to coarse
- the solution was then cooled to 10°C and added sodium chloride to 0.5 %. Then drops of 5.5 M HC1 was added, with carefully magnetic stirring until pH 1.8. A white precipitate was formed.
- the material suspension was then stored for 30 minutes and sieved on 400-mesh filtration cloth and pressed carefully by hand. The material was a pasty yellow mass, which turned to fine bright fibers after pressing.
- the acid material was then transferred to a 250 ml vessel and added water to 200 ml and then neutralized pH 7 with solid soda ash under magnetic stirring. The filtrate was then cooled to 10 °C and precipitated on stirring with lOOvolume % isopropyl alcohol in a ratiol :l . Large fibers were precipitated.
- the commercial feed (13% moisture content) was fortified with vitamins and minerals required for growth and had a raw protein content of about 18-19%, a digestible protein content of 14-15%), a starch content of 40-50%, and a raw fat content of about 2.6%.
- Durvillea antarctica standard extract had an intrinsic viscosity of 7.0 g/dl which corresponds to an estimated weight average molecular weight of 210,000 Daltons using the Mark Houwink equation.
- This Durvilla alginate sample had a mole fraction content for mannuronate (M) units of 0.63 and for guluronate (G) units of 0.37.
- the fractional content of the M to M linkages, F(MM), was 0.44.
- the fractional content for the G to G linkages, F(GG) was 0.18.
- Durvillea antarctica water extract or Durvillea water extract obtained by selective precipitation of an alginate fraction having an increased the M content, had an intrinsic viscosity of 4.7 g/dl which corresponds to an estimated weight average molecular weight of 85,000 Daltons using the Mark Houwink equation.
- This Durvillea water extract alginate sample had a mole fraction content for mannuronate (M) units of 0.88 and for guluronate (G) units of 0.12.
- M mannuronate
- G guluronate
- the fractional content for the M to M linkages, F(MM) was 0.80.
- the fractional content for the G to G linkages, F(GG) was 0.04.
- the fraction content of the M to G linkage, F(MG) which is equal to the fractional content of the G to M linkage F(GM), was 0.08.
- Lessonia nigrescens standard extract had an intrinsic viscosity of 13.4 g/dl which corresponds to an estimated weight average molecular weight of 370,000 Daltons using the Mark Houwink equation.
- This Lessonia alginate sample had a mole fraction content for mannuronate (M) units of 0.55 and for guluronate (G) units of 0.45.
- the fractional content of the M to M linkages, F(MM) was 0.35.
- the fractional content for the G to G .linkages, F(GG) was 0.25.
- the fractional content of the M to G linkage, F(MG) which is equal to the fractional content of the G to M linkage F(GM), was 0.20.
- the alginate intrinsic viscosity was determined using the method disclosed in Alginates as immobilization materials - A study of some molecular and functional properties (Martinsen, Anita) Thesis; NTH - University of Trondheim, 1990. The weight average molecular weight was estimated based on the intrinsic viscosity data and the Mark Howink
- the pigs were immunized (at 7 weeks of age) and they were given a booster injection four weeks later (at 11 weeks of age). All pigs were immunized intramuscularly with 0.5 ml of a mixture of 0.25 ml Pneumabort K ® (102BY0002, Fort Dodge Laboratories) containing equine herpes virus 1 (EHV) and 0.25 ml Human serum albumin
- HSA Prevacun F ® (02702 IE, Hoechst
- Roussel Vet, Germany containing influenza virus A/Equi 1 , A/Equi 2/M, A/Equi 2/F (EIV) and 1.0 ml Diphteri/Tetanus vaccine ® (DT9169al, SBL Vaccin AB, Sweden) containing diphtheria toxoid (30 Lf/ml) and tetanus toxoid (7.5 Lf/ml).
- HSA Human serum albumin
- DIF Diphteriae toxoid
- Blood samples were collected at two week intervals for serology, haematology, and for functional characterization of phagocytes and lymphocytes. Serum was isolated and stored at - 20°C until processed. Stabilized (heparinized and EDTA) blood samples were collected in the morning and analysed immediately. The blood samples were analysed (Technicon H-1) at the Central Clinical Laboratory at The Norwegian School of Veterinary Science, Oslo. The total leukocyte count (WBC x 10 9 /L), number (x 10 9 /L) of monocytes, neutrophils and eosinophils were measured electronically and the number of lymphocytes and the relative number (%) of lymphocytes, monocytes, neutrophils and eosinophils were estimated.
- WBC x 10 9 /L The total leukocyte count (WBC x 10 9 /L), number (x 10 9 /L) of monocytes, neutrophils and eosinophils were measured electronically and the number of lymphocytes and the relative number (%) of lymph
- E. coli suspension test kit. All vials were shaken and the test samples were
- test kit 20 ⁇ il precooled stabilized and opsonized E. coli suspension
- test samples were incubated for 10 minutes at 37°C in a water bath. All
- the supernatant was decanted and 200 ⁇ l of DNA staining solution was added, the samples were mixed and incubated 10 minutes on ice (light protected).
- the cells were analysed by flow cytometry (FACScan , LYSIS software) using the blue-green excitation light (488 nm). The percentage of cells having produced reactive oxygen metabolites was analysed as well as their mean fluorescence intensity.
- Figure 1 shows mean weight for the four groups of pigs as a function of feeding time. A significant weight increase was found for pigs in the Durvillea water extract group and Lessonia group compared to the control group. The weight difference is deemed statistically significant after week 3, however Figure 1 shows a trend in weight gain consistent with the Durvillea water extract group and the Lessonia group increasing in weight more rapidly than the control group after week 1. While the actual weight differential between the Durvillea group and the control group is not as dramatic as that seen for the Durvillea water extract group and Lessonia group, it should be noted that the mean weight of the Durvillea group was consistently higher than the control.
- the individual pigs in the control group had a higher variability in weight compared to individuals in the three groups which had alginate- containing feed which suggests that some individuals in the control group had a reduced immune response since they were less able to cope with trauma and/or stress.
- the hormone Cortisol in pigs partitions nutrients away from muscle and adipose tissue to allow the animal to cope with disease stress.
- Figures 2 through 4 show data obtained by analyzing the blood for total white blood cells, monocytes and lymphocytes. While not statistically significant, Figure 2 indicates that the total white blood cells for Durvillea water extract group is higher than the control group.
- the increase white blood cell count observed for the Durvillea water extract group is due to significant increases in both monocytes (Figure 3) and lymphocytes ( Figure 4) after 6 and 10 weeks, respectively, for the Durvillea water extract group compared to the control group.
- the lymphocytes for the Lessonia group show a delayed increase (week 10) compared to the Durvillea water extract group..
- the blood taken from the Durvillea water extract group (and control group) were also assayed for phagocytic activity, and significant increases were measured for the Durvillea water extract group compared to the control group at week 4 as seen in Figure 5.
- the oxidative burst data shown in Figure 6 further supports the higher level phagocytic response for the pigs fed the Durvillea water extract compared to the control at both week 4 and week 8.
- the sustained increased oxidative burst at week 4 and week 8 for the Durvillea water extract group compared to the control group is significant since the underlying chemical processes associated with respiratory burst are necessary to kill some types of bacteria and indicates improved effectiveness of phagocytosis.
- Figure 7 indicates the immune response to vaccination.
- the immunoresponse to injection of Human Serum Albumin experimental vaccine (Figure 7) shows a significant increase at week 8 for the Durvillea water extract group and the Lessonia group which indicates an improved immune response compared to the control.
- Durvillea water extract alginate (as described in Example 5) was dissolved in water, and after a short sonication treatment, the solution containing the dissolved alginate at a concentration of 4.2 gram of alginate per liter was sprayed onto commercial feed particles (Skretting/Nutreco, Dirdal, Norge) to give 0.02% and 0.06% alginate (% by weight) on the feed.
- the feed particles were air-dried for two days before oral administration to newly hatched spotted wolffish (Anarhichas minor) fish fry.
- This Durvillea antarctica water extract had an intrinsic viscosity of 8.3 dl/g which corresponds to an estimated weight average molecular weigh of 160 000 Daltons using the Mark Houwink equation.
- This Durvillea water extract alginate sample had a mole fraction content for mannuronate (M) units of 0.89 and for guluronate (G) units of 0.1 1.
- the fractional content for the M to M linkages, F(MM), was 0.81.
- the fractional content for the G to G linkages, F(GG), was 0.03.
- the average weight per fish was approximately 0.4 g at the start of the feeding study.
- the fry were weighed every 10 days (wet weight) during the study.
- the test conditions included three different feeds: control (0% alginate), 0.02% alginate and 0.06% alginate.
- An additional group of fish that fed the control feed were bath treated twice during the sixty day feeding period by transferring the fish into a bath containing 0.1 g of alginate per liter of seawater with a treatment for 12-24h per treatment cycle then in the feeding study.
- the fish that were fed alginate-containing feed showed a higher specific rate of growth of 5.197 % growth per day (for 0.02% alginate) and 5.247% growth per day (for 0.06% alginate) compared to fish that were fed the control feed without added alginate (4.857 % growth per day) over the 60 day growth period.
- the fish that were intermittently bath treated twice during the 60 day study showed no significant different in their specific rate of growth compared to the control group (4.745 % growth per day vs. 4.857 % growth per day, respectively).
- the specific growth rate in Figure 8 was calculated as the percentage daily growth according to the following formula: 100% times [In (weight at the end of the study) minus In (weight at day zero of the study)] divided by the number days in the study (note: In is natural log).
- Durvillea water extract alginate (as described in Example 5) was dissolved in water to give a concentration of alginate of 3 %.
- This Durvillea antarctica water extract had an intrinsic viscosity of 4,7 dl/g which corresponds to an estimated weight average molecular weigh of 85 000 Daltons using the Mark Houwink equation.
- This Durvillea water extract alginate sample had a mole fraction content for mannuronate (M) units of 0.88 and for guluronate (G) units of 0.12.
- M mannuronate
- G guluronate
- the fractional content for the M to M linkages, F(MM) was 0.80.
- the fractional content for the G to G linkages, F(GG) was 0.04.
- the fraction content of the M to G linkage, F(MG) which is equal to the fractional content of the G to M linkage F(GM), was 0.08.
- Portions of approximately 1200 grams of commercial feed (Biomar Ecoweaner EMB 16244) were spray coated with different amounts of the alginate solution in a bench top fluidised bed reactor under the following conditions: Air flow sufficient to fluidise the particles, 40-50 degrees Celsius, and flow of alginate solution of 60 ml per hour. Dry feed particles were recovered with different concentrations of the alginate (0.01 %, 0.06 % and 0.10 %) as calculated based on the alginate concentration and amount of alginate solution coated per weight of dry powder originally charged. For the lowest concentration an alginate solution diluted to 0.5 % was used instead. The control sample was used without further treatment. Feed with particle size of both 0.6 mm and 1.0 mm was used for the early and late feeding period respectively. The coated and uncoated feed particles were visually inspected in a microscope, and no difference could be seen in appearance or in particle size. The dry matter content immediately after processing was slightly higher in the coated particles (95 %) compared to the uncoated (90 %).
- the solution of labelled alginate was filtered through a 0.45-micron filter before further labelling with l25 Iodine ( l25 I).
- 50 micro litres of iodogen (l,3,4,6-tetrachloro-3alfa, 6alfa-diphenylglycoluril) was added to an Ellermann tube. When the solution was evaporated from the tube, it was flushed 5 times with water and dried with compressed air.
- the tube was added 50 micro litres of phosphate buffer solution, 4 micro litres of 125 I , and 2 ml of the MPHBIM labelled alginate solution. The reaction was stopped after 1 hour by adding 100 micro litres of 0.1 M sodium bisulphite.
- Non-reacted isotope compounds were removed with gel chromatography using a Sephadex G- 25 material.
- the non-reactor compounds and labelled alginate were identified using a gamma counter.
- Feed particles were coated with the I 2 " MPHBIM-labelled alginate as in example 6.
- the coated feed particles were shaken in seawater for 5 minutes, and after sedimentation of samples of the water were taken for analysis in gamma counter.
- Six parallels were analysed and the loss of alginate was measured from 5.2 % to 8.0 %. The experimental loss in the feeding trials is thus considered to be very low since the larvae normally consume the feed in seconds.
- Newly hatched larvae of spotted wolffish (ca. 0.3 gram) were placed in 12 containers, about 80 in each.
- the containers measured 40 x 20 cm, and was individually supplied with continuously running water in one end so that a continuously water current through the container was obtained. Water temperature was 8 degrees Celsius throughout the experiment.
- Non-consumed feed and faeces was continuously removed.
- Three parallel containers were given feed with each concentration and three containers were given the control feed. Feed was given several times (approximately every hour) during the daytime to ensure feed was not a limiting factor. Every 10 days the weight of 30 larvae was measured. The experiment lasted for 60 days. Bars marked with an "*" indicates a significant difference (p ⁇ 0.05). Results of specific growth rate are given in Figure 9.
- Durvillea water extract alginate (as described in Example 5) was dissolved in water, and portions of commercial feed (Biomar Ecoweaner EMB 16244) were coated with different amounts of the alginate solution in a bench top fluidised bed reactor. Dry feed particles were recovered with different concentrations of the alginate (0.01 %, 0.06 % and 0.10 %) as in Example 7.
- Cod larvae were acclimatized for 10 days in total before start of experiment. During this initial 10-day period, the larvae were all fed the control feed and reached a weight of 0.5- 1.0 g. 3 days before the start of the experiment the larvae were divided into 12 round containers (40 cm diameter and height of 60 cm) of 30 litres with about 70 larvae in each container. Every container was equipped with plastic sieves in the bottom. The water volume varied between 15 and 20 litre throughout the experiment. In the same period the water temperature followed the natural sea temperature and increased from 8-12 degrees Celsius. The containers had individual water supply of about 1.5 litres per minute and constant light exposure. Non-consumed feed was removed and the containers cleaned if necessary. When the weight of the larvae was measured the containers were emptied and thoroughly cleaned.
- the base weight for 30 larvae in each container was determined prior to the start of the test feed. Three parallel containers were given feed with each concentration of alginate and three containers were given the control feed. Feed was given several times during the daytime (approximately every hour to ensure feed was not a limiting factor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Farming Of Fish And Shellfish (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02799860A EP1460964A2 (en) | 2001-11-30 | 2002-11-21 | Oral immunostimulation of mammals, birds, fish and reptiles from (1-4) linked b -d-mannuronic acid |
US10/497,212 US7816340B2 (en) | 2001-11-30 | 2002-11-21 | Oral immunostimulation of fish from (1-4) linked β-D-mannuronic acid |
JP2003546778A JP2005522189A (en) | 2001-11-30 | 2002-11-21 | (1-4) Oral immunostimulation of mammals, birds, fish and reptiles from conjugated β-D-mannuronic acid |
AU2002364493A AU2002364493A1 (en) | 2001-11-30 | 2002-11-21 | ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ss-D-MANNURONIC ACID |
CA002468575A CA2468575A1 (en) | 2001-11-30 | 2002-11-21 | Oral immunostimulation of mammals, birds, fish and reptiles from (1-4) linked .beta.-d-mannuronic acid |
US12/883,308 US20110046085A1 (en) | 2001-11-30 | 2010-09-16 | Oral Immunostimulation of Fish from (1-4) Linked Beta-D-Mannuronic Acid |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20015875 | 2001-11-30 | ||
NO20015875A NO326145B1 (en) | 2001-11-30 | 2001-11-30 | Method of stimulating weight gain in mammals, birds and reptiles. |
NO20022893 | 2002-06-17 | ||
NO20022893A NO320671B1 (en) | 2001-11-30 | 2002-06-17 | Method of stimulating weight gain in fish. |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/883,308 Continuation US20110046085A1 (en) | 2001-11-30 | 2010-09-16 | Oral Immunostimulation of Fish from (1-4) Linked Beta-D-Mannuronic Acid |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003045272A2 true WO2003045272A2 (en) | 2003-06-05 |
WO2003045272A3 WO2003045272A3 (en) | 2003-09-12 |
Family
ID=26649338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO2002/000432 WO2003045272A2 (en) | 2001-11-30 | 2002-11-21 | ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ß-D-MANNURONIC ACID |
Country Status (8)
Country | Link |
---|---|
US (2) | US7816340B2 (en) |
EP (1) | EP1460964A2 (en) |
JP (2) | JP2005522189A (en) |
CN (1) | CN1287680C (en) |
AU (1) | AU2002364493A1 (en) |
CA (1) | CA2468575A1 (en) |
NO (1) | NO320671B1 (en) |
WO (1) | WO2003045272A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3649869A1 (en) | 2018-11-08 | 2020-05-13 | Biochem Zusatzstoffe Handels- und Produktionsges. mbH | Powder composition and gel composition comprising aquatic photosynthesizing organisms |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005145885A (en) * | 2003-11-14 | 2005-06-09 | Japan Science & Technology Agency | Immunologic mechanism activator comprising alginic acid oligomer |
JP5147218B2 (en) * | 2006-11-13 | 2013-02-20 | ハイドロックス株式会社 | Seaweed-derived immunostimulant and anti-inflammatory agent |
WO2011006261A1 (en) * | 2009-07-17 | 2011-01-20 | Ocean Harvest Technology (Canada) Inc. | Natural and sustainable seaweed formula that replaces synthetic additives in fish feed |
JO3676B1 (en) * | 2009-07-27 | 2020-08-27 | Arc Medical Devices Inc | Pharmaceutical compositions comprising modified fucans and methods relating thereto |
DE102014200922A1 (en) * | 2014-01-20 | 2015-07-23 | Fim Biotech Gmbh | Use of clay mineral as feed additive and / or as supplementary feed for aquatic organisms |
CA2987932C (en) | 2015-06-03 | 2024-01-16 | Ewos Innovation As | Oral delivery system for bioactive agents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6236152A (en) * | 1985-04-04 | 1987-02-17 | Nichiden Kagaku Kk | Feed for pisciculture |
JPS62275656A (en) * | 1986-05-23 | 1987-11-30 | Kimitsu Kagaku Kenkyusho:Kk | Production of feed |
JP2840851B2 (en) | 1989-03-23 | 1998-12-24 | 池田糖化工業株式会社 | Fish immunopotentiator and fish culture feed |
WO1991011205A1 (en) * | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
DE4204012A1 (en) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | MITOGEN-FREE SUBSTANCE, THEIR PRODUCTION AND USE |
GB9221163D0 (en) * | 1992-10-08 | 1992-11-25 | Nobipol And Protan Biopolymer | Dna compounds |
JP2824185B2 (en) | 1993-03-22 | 1998-11-11 | 旭化成工業株式会社 | Fish immunostimulants |
JPH08308510A (en) * | 1995-05-11 | 1996-11-26 | Maruha Corp | Artificial formula feed for snails containing alginic acid |
GB9708773D0 (en) * | 1997-04-30 | 1997-06-25 | Reckitt & Colmann Prod Ltd | Organic compositions |
NO305033B1 (en) * | 1997-05-09 | 1999-03-22 | Algipharma As | Process for the preparation of uric acid blocks from alginate |
US6338856B1 (en) * | 1998-02-27 | 2002-01-15 | Texas Tech University | Seaweed supplement diet for enhancing immune response in mammals and poultry |
US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
US6706263B2 (en) * | 1999-04-30 | 2004-03-16 | Kibow Biotech Inc. | Composition for alleviating symptoms of uremia in patients |
KR100501584B1 (en) | 2000-02-03 | 2005-07-18 | (주)케이비피 | Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same |
-
2002
- 2002-06-17 NO NO20022893A patent/NO320671B1/en not_active IP Right Cessation
- 2002-11-21 EP EP02799860A patent/EP1460964A2/en not_active Withdrawn
- 2002-11-21 WO PCT/NO2002/000432 patent/WO2003045272A2/en active Search and Examination
- 2002-11-21 CN CNB028239342A patent/CN1287680C/en not_active Expired - Fee Related
- 2002-11-21 US US10/497,212 patent/US7816340B2/en not_active Expired - Fee Related
- 2002-11-21 CA CA002468575A patent/CA2468575A1/en not_active Abandoned
- 2002-11-21 AU AU2002364493A patent/AU2002364493A1/en not_active Abandoned
- 2002-11-21 JP JP2003546778A patent/JP2005522189A/en active Pending
-
2010
- 2010-02-08 JP JP2010025791A patent/JP2010110332A/en active Pending
- 2010-09-16 US US12/883,308 patent/US20110046085A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3649869A1 (en) | 2018-11-08 | 2020-05-13 | Biochem Zusatzstoffe Handels- und Produktionsges. mbH | Powder composition and gel composition comprising aquatic photosynthesizing organisms |
Also Published As
Publication number | Publication date |
---|---|
AU2002364493A1 (en) | 2003-06-10 |
NO20022893D0 (en) | 2002-06-17 |
NO320671B1 (en) | 2006-01-16 |
JP2005522189A (en) | 2005-07-28 |
WO2003045272A3 (en) | 2003-09-12 |
US20050026865A1 (en) | 2005-02-03 |
CA2468575A1 (en) | 2003-06-05 |
CN1287680C (en) | 2006-12-06 |
US7816340B2 (en) | 2010-10-19 |
EP1460964A2 (en) | 2004-09-29 |
NO20022893L (en) | 2003-06-02 |
JP2010110332A (en) | 2010-05-20 |
US20110046085A1 (en) | 2011-02-24 |
CN1599564A (en) | 2005-03-23 |
AU2002364493A8 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110046085A1 (en) | Oral Immunostimulation of Fish from (1-4) Linked Beta-D-Mannuronic Acid | |
US10688140B2 (en) | Composition to improve gut health and animal performance and methods of making the same | |
CN108853486B (en) | Formula product with function of enhancing immunity | |
US20090227535A1 (en) | Process for producing natural immunobiotic extract and uses thereof | |
JP2002511051A (en) | Compositions of plant carbohydrates as food supplements | |
US7893038B2 (en) | Oral immunostimulation of mammals birds and reptiles from (1-4) linked β-D-mannuronic acid | |
KR20010071331A (en) | Additives for crustacean or fish feeds and feeds | |
Manayi et al. | Immunomodulation effect of aqueous extract of the artist's conk medicinal mushroom, Ganoderma applanatum (Agaricomycetes), on the rainbow trout (Oncorhynchus mykiss) | |
EP3755343A1 (en) | New process of preparation of glycan composition & uses thereof | |
KR101088442B1 (en) | Fermented Feed additives using Ecklonia cava and the method of producting it, feed comprising it | |
EP1633373B1 (en) | Pharmaceutical composition comprising glucan derived from microalgae | |
US20090092641A1 (en) | Uses of natural immunobiotic extract | |
JP2004215506A (en) | Sea weed extract | |
KR0157366B1 (en) | Method for improvement of fleshy chicken | |
EP4342477A1 (en) | Immunostimulator and glucan composition production method | |
RU2502322C1 (en) | Method for production of fodder additive for prevention and therapy of animals and birds diseases | |
JP2024149402A (en) | Oral Compositions | |
KR100327966B1 (en) | Nutrients containing water-soluble chitosan for pig and using method thereof | |
KR20220163926A (en) | body fat reducer | |
Class et al. | Patent application title: Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same Inventors: John O'Doherty (Belfield, IE) John O'Sullivan (Tralee, IE) Aditya Julka (Tralee, IE) Assignees: BIOATLANTIS LIMITED | |
JP2006028070A (en) | Antineoplastic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2468575 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-500800 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028239342 Country of ref document: CN Ref document number: 2003546778 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002799860 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10497212 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002799860 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |